Amador Bioscience Appoints Dr. Lorin K. Roskos as Chief Scientific Officer and President of Quantitative Clinical Pharmacology

Amador Bioscience, a next-generation CRO focused on translational science and clinical development, announced the appointment of Dr. Lorin K. Roskos as Chief Scientific Officer (CSO) and President of Quantitative Clinical Pharmacology (QCP), where he will lead the global quantitative pharmacology team.

Dr. Lorin K. Roskos, CSO of AMADOR BIOSCIENCE and President of QCP

Dr. Roskos is one of the most respected leaders in the biopharmaceutical industry, with over 30 years of experience in pharmaceutical R&D and management. He is a globally renowned expert in translational science, clinical pharmacology, and bioanalysis. Dr. Roskos has held executive positions in drug discovery, nonclinical development, and clinical development at leading multinational pharmaceutical companies and small biotechnology firms, including Amgen, AstraZeneca, and Exelixis. He possesses extensive experience across multiple therapeutic areas, such as oncology, respiratory diseases, autoimmune disorders, inflammation, cardiovascular conditions, renal diseases, metabolic disorders, and infectious diseases, making significant contributions to the successful development and global market launch of numerous drugs. Dr. Roskos has published more than 100 original research articles, reviews, and book chapters, and has received numerous honors and awards recognizing his outstanding contributions to drug research and development.

"We are delighted that Dr. Roskos will serve as the Chief Scientific Officer (CSO) and lead the QCP team at AMADOR BIOSCIENCE. He enjoys a high reputation in translational science and clinical development, backed by extensive knowledge and rich experience. This is invaluable to AMADOR BIOSCIENCE’s mission of accelerating global drug development and providing patients with better treatment options," said Dr. Wang Bing, CEO of AMADOR BIOSCIENCE.

Dr. Roskos also expressed his enthusiasm, stating, “Amador Bioscience is a new-generation CRO rapidly advancing on the global stage. I am honored to ‘come on board’ and look forward to working closely with the team to leverage our expertise and experience in translational science and clinical development, helping more drugs achieve rapid and successful approval so that patients may benefit sooner.”

As the newly appointed Chief Scientific Officer and President of Quantitative Clinical Pharmacology, Dr. Roskos will bring to Amador Bioscience extensive expertise in clinical pharmacology, quantitative pharmacology, systems pharmacology, and translational medicine. He will build a team that reflects Amador’s industry leadership, spearhead the development and implementation of Amador’s global clinical pharmacology strategy, advance the company’s operational capabilities, and identify additional growth opportunities across its business lines. Dr. Roskos’s appointment will strengthen Amador Bioscience’s commitment to providing biopharmaceutical companies with the highest-quality translational science and clinical development solutions. Leveraging Dr. Roskos’s extensive industry and senior management experience, Amador Bioscience, as a next-generation global CRO, will continue to develop and expand.

AMADOR BIOSCIENCE is a globally leading next-generation CRO specializing in translational and clinical development.

As a preferred partner for the successful development of innovative drugs, Amador Bioscience provides end-to-end services compliant with international standards for new drug development in China, Europe, and the United States. These services include translational and quantitative pharmacology, bioanalysis and biomarkers, regulatory submissions, biostatistics, and clinical development. The company offers comprehensive strategies and execution for clinical development from preclinical stages to market launch, scientifically optimizing dose selection, target identification, and patient stratification. By leveraging a globally unified technical platform, management system, and quality standards, Amador Bioscience enhances the efficiency and success rate of new drug R&D. Its client base ranges from leading startup biotech companies to large multinational pharmaceutical enterprises. To date, the Amador team has successfully completed over 210 marketing authorization applications (NDA, BLA, MAA) for domestic and international clients in China, the United States, Europe, and Japan.

Amador Bioscience has established operational facilities in multiple locations worldwide, including Pleasanton, CA; Ann Arbor, MI; and Germantown, MD in the United States; Hangzhou, Shanghai, and Beijing in China; and Limburg, Belgium in Europe.